Global Information
회사소개 | 문의

폐동맥 고혈압 : 역학적 예측

Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast to 2027

리서치사 DelveInsight Business Research LLP
발행일 2018년 06월 상품 코드 534965
페이지 정보 영문 56 Pages
가격
US $ 3,250 ₩ 3,668,600 PDF by E-mail (Single User License)
US $ 6,500 ₩ 7,337,200 PDF by E-mail (Site License)
US $ 9,750 ₩ 11,005,800 PDF by E-mail (Global License)


폐동맥 고혈압 : 역학적 예측 Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast to 2027
발행일: 2018년 06월 페이지 정보 : 영문 56 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계 폐동맥 고혈압(PAH)의 역학적 예측에 대해 분석했으며, 질환 개요 및 현재 치료 방법/알고리즘, 세계 전체 및 주요 국가(미국·유럽 국가·일본)의 환자 수·리스크 환자 수 동향 전망, 향후 의약품 개발·임상시험 전망 등에 대해 조사하여 전해드립니다.

제1장 분석 개요

제2장 폐동맥 고혈압(PAH) : 개요

  • 징후와 증상
  • 폐동맥 고혈압(PAH)의 분류
  • PAH의 기능적 분류
  • 병인
  • 위험인자
  • 병태생리
  • 진단 방법
  • 치료 방법

제3장 역학과 환자 인구

  • 주요 조사 결과
  • 환자 인구와 예측 파라미터
  • 주요 7개국(7MM)의 폐동맥 고혈압(PAH) 환자 수
    • 미국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
    • 일본

제4장 폐동맥 고혈압(PAH)의 역학 : 국가별

  • 미국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제5장 부록

제6장 DelveInsight의 서비스 내용

제7장 면책사항

제8장 DelveInsight 소개

KSA 18.06.15

영문목차

DelveInsight's ‘Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pulmonary Arterial Hypertension in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Pulmonary Arterial Hypertension are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Pulmonary Arterial Hypertension Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Prevalent cases, Sub-type specific prevalent cases and Gender specific prevalence) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total prevalent population of Pulmonary Arterial Hypertension was found to be 70,557 in the year 2016 in 7MM.

Report Scope:

  • The report covers detailed overview of Pulmonary Arterial Hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Pulmonary Arterial Hypertension in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by sub-type i.e., Idiopathic PAH, Drug/Toxin Induced, CTD Associated PAH, Portopulmonary Hypertension associated PAH, CHD associated PAH, Heritable PAH and Gender-specific Pulmonary Arterial Hypertension in 7MM

Key strengths:

  • 10 Year Forecast of Pulmonary Arterial Hypertension epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of PAH
  • Prevalent Cases according to segmentation: Sub-type specific & Gender- specific prevalence
  • Diagnosed cases of PAH

Key assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

  • 2.1. Introduction
  • 2.2. Signs and Symptoms
  • 2.3. Classification of Pulmonary Arterial Hypertension (PAH)
  • 2.4. Functional Classification of PAH
  • 2.5. Etiology
  • 2.6. Risk factors
  • 2.7. Pathophysiology
  • 2.8. Diagnosis

3. Epidemiology and Patient Population

  • 3.1. Key Findings
  • 3.2. Population and Forecast Parameters
  • 3.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

4. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

  • 4.1. The United States
    • 4.1.1. Total Prevalent Patient Population of PAH in the United States
    • 4.1.2. Sub-type Specific Prevalence of PAH in the United States
    • 4.1.3. Gender specific Prevalence of PAH in the United States
  • 4.2. Germany
    • 4.2.1. Total Prevalent Patient Population of PAH in Germany
    • 4.2.2. Sub-type Specific Prevalence of PAH in Germany
    • 4.2.3. Gender specific Prevalence of PAH in Germany
  • 4.3. France
    • 4.3.1. Total Prevalent Patient Population of PAH in France
    • 4.3.2. Sub-type Specific Prevalence of PAH in France
    • 4.3.3. Gender specific Prevalence of PAH in France
  • 4.4. Italy
    • 4.4.1. Total Prevalent Patient Population of PAH in Italy
    • 4.4.2. Sub-type Specific Prevalence of PAH in Italy
    • 4.4.3. Gender specific Prevalence of PAH in Italy
  • 4.5. Spain
    • 4.5.1. Total Prevalent Patient Population of PAH in Spain
    • 4.5.2. Sub-type Specific Prevalence of PAH in Spain
    • 4.5.3. Gender specific Prevalence of PAH in Spain
  • 4.6. The United Kingdom
    • 4.6.1. Total Prevalent Patient Population of PAH in the UK
    • 4.6.2. Sub-type Specific Prevalence of PAH in the UK
    • 4.6.3. Gender specific Prevalence of PAH in the United Kingdom
  • 4.7. Japan
    • 4.7.1. Total Prevalent Patient Population of PAH in Japan
    • 4.7.2. Sub-type Specific Prevalence of PAH in Japan
    • 4.7.3. Gender specific Prevalence of PAH in Japan

5. Appendix

  • 5.1. Report Methodology

6. DelveInsight Capabilities

7. Disclaimer

8. About DelveInsight

List of Tables

  • Table 1: Total Prevalent Patient Population of PAH in 7MM (2016-2027)
  • Table 2: Total Prevalent Population of PAH in the United States (2016-2027)
  • Table 3: Sub-type Specific Prevalence of PAH in the United States (2016-2027)
  • Table 4: Gender specific Prevalence of PAH in the United States (2016-2027)
  • Table 5: Total Prevalent Population of PAH in Germany (2016-2027)
  • Table 6: Sub-type Specific Prevalence of PAH in Germany (2016-2027)
  • Table 7: Gender specific Prevalence of PAH in Germany (2016-2027)
  • Table 8: Total Prevalent Population of PAH in France (2016-2027)
  • Table 9: Sub-type Specific Prevalence of PAH in France (2016-2027)
  • Table 10: Gender specific Prevalence of PAH in France (2016-2027)
  • Table 11: Total Prevalent Population of PAH in Italy (2016-2027)
  • Table 12: Sub-type Specific Prevalence of PAH in Italy (2016-2027)
  • Table 13: Gender specific Prevalence of PAH in Italy (2016-2027)
  • Table 14: Total Prevalent Population of PAH in Spain (2016-2027)
  • Table 15: Sub-type Specific Prevalence of PAH in Spain (2016-2027)
  • Table 16: Gender specific Prevalence of PAH in Spain (2016-2027)
  • Table 17: Total Prevalent Population of PAH in the UK (2016-2027)
  • Table 18: Sub-type Specific Prevalence of PAH in the UK (2016-2027)
  • Table 19: Gender specific Prevalence of PAH in the UK (2016-2027)
  • Table 20: Total Prevalent Population of PAH in Japan (2016-2027)
  • Table 21: Sub-type Specific Prevalence of PAH in Japan (2016-2027)
  • Table 22: Gender specific Prevalence of PAH in Japan (2016-2027)

List of Figures

  • Figure 1: Classification of Pulmonary Arterial Hypertension (PAH)
  • Figure 2: Functional Classification of PAH
  • Figure 3: Risk Factors of Pulmonary Arterial Hypertension
  • Figure 4: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
  • Figure 5: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
  • Figure 6: Total Prevalent Patient Population of PAH in 7MM (2016-2027)
  • Figure 7: Prevalence of PAH in the United States (2016-2027)
  • Figure 8: Sub-type Specific Prevalence of PAH in the United States (2016-2027)
  • Figure 9: Gender specific Prevalence of PAH in the United States (2016-2027)
  • Figure 10: Total Prevalent Population of PAH in Germany (2016-2027)
  • Figure 11: Sub-type Specific Prevalence of PAH in Germany (2016-2027)
  • Figure 12: Gender specific Prevalence of PAH in Germany (2016-2027)
  • Figure 13: Total Prevalent Population of PAH in France (2016-2027)
  • Figure 14: Sub-type Specific Prevalence of PAH in France (2016-2027)
  • Figure 15: Gender specific Prevalence of PAH in France (2016-2027)
  • Figure 16: Total Prevalent Population of PAH in Italy (2016-2027)
  • Figure 17: Sub-type Specific Prevalence of PAH in Italy (2016-2027)
  • Figure 18: Gender specific Prevalence of PAH in Italy (2016-2027)
  • Figure 19: Total Prevalent Population of PAH in Spain (2016-2027)
  • Figure 20: Sub-type Specific Prevalence of PAH in Spain (2016-2027)
  • Figure 21: Gender specific Prevalence of PAH in Spain (2016-2027)
  • Figure 22: Total Prevalent Population of PAH in the UK (2016-2027)
  • Figure 23: Sub-type Specific Prevalence of PAH in the UK (2016-2027)
  • Figure 24: Gender specific Prevalence of PAH in the United Kingdom (2016-2027)
  • Figure 25: Total Prevalent Population of PAH in Japan (2016-2027)
  • Figure 26: Sub-type Specific Prevalence of PAH in Japan (2016-2027)
  • Figure 27: Gender specific Prevalence of PAH in Japan (2016-2027)
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research